Beijing Cancer hospital ( Site 3000)

Beijing, Beijing Municipality 100142

1 studies enrolling now · 1 studies all time

What they study most

DLBCL, Diffuse Large B-Cell Lymphoma

Studies at this site

• A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) — Recruiting now